Pacific Biosciences
PACB
250 hedge funds and large institutions have $2B invested in Pacific Biosciences in 2022 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 92 increasing their positions, 70 reducing their positions, and 48 closing their positions.
37% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $15.5M
31% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 70
7.8% more ownership
Funds ownership: 93.09% → 100.89% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 48
2% less funds holding
Funds holding: 256 → 250 (-6)
52% less capital invested
Capital invested by funds: $4.2B → $2B (-$2.2B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$92.6M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$38.3M |
| 3 |
Two Sigma Investments
New York
|
+$31.1M |
| 4 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$30.6M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$112M |
| 2 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$72.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$35.5M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$28.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$17.6M |
PACB Hedge Fund Activity: Q1 2022 in Review
250 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2022, worth a combined $2B — down 52% from $4.2B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of PACB and 44 opened new positions — a net loss of 4 holders — while 70 trimmed existing stakes and 92 added.
The largest buyer was Jackson Square Partners, adding an estimated $92.6M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $112M sold.
- 250 institutional investors held Pacific Biosciences (PACB) as of Q1 2022, down from 256 in Q4 2021.
- Funds reported $2B of Pacific Biosciences stock for Q1 2022, down 52% quarter-over-quarter.
- 44 funds opened new Pacific Biosciences positions in Q1 2022 and 48 closed out, a net change of -4 holders.
- The largest Pacific Biosciences buyer in Q1 2022 was Jackson Square Partners, an estimated $92.6M added.
- The largest Pacific Biosciences seller in Q1 2022 was William Blair Investment Management, an estimated $112M sold.
Based on aggregated 13F filings for Q1 2022.